Invizyne Technologies, creator of SimplePath, a biomanufacturing platform, filed with the SEC on Feb. 9 for a $17 million IPO. The Monrovia, California-based company, which has applied to list its shares on the Nasdaq, is advised by Golenbock Eiseman Assor Bell & Peskoe partner Andrew Hudders. The underwriters, led by Public Ventures, are represented by the Law Offices of Aaron A. Grunfeld.
Biotech & Pharmaceuticals
February 12, 2024, 10:31 AM